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Cisplatin is the most active single agent in cervical cancer,
yielding a 21–31% response rate. However, in patients with a
pelvic recurrence within previously irradiated areas the response
rate is lower than in patients with extrapelvic sites of disease. In
addition, responses in pelvic recurrences are usually partial at best,
and of brief, median 4–6 months, duration. In in vitro and in vivo
models marked synergism has been demonstrated of the simulta-
neous application of heat and cisplatin (Wallner et al, 1986, 1987;
Baba et al, 1989). It appears that cytotoxic synergism is greatest
when cells are exposed to cisplatin and hyperthermia simultane-
ously (Dahl, 1995). Synergism can already be demonstrated both
in vitro and in vivo at 41 and 42°C, and there appears to be a linear
increase in cisplatin cytotoxicity with increasing temperature
(40–45°C). With the use of local deep hyperthermia, tumour
temperatures of about 42–45°C can be reached and tolerated for
30–60 min. In addition, with the use of local hyperthermia and the
systemic administration of chemotherapy, maximum synergism
can be achieved, without increasing systemic side-effects, particu-
larly on bone marrow and kidneys (Dahl, 1995). Therefore, the
approach of combining local hyperthermia with chemotherapy
provides a means of targeting and selective toxicity, thereby
increasing cell kill in the tumour. In the present study, we investi-
gated the maximum tolerated dose and the potential of the
combination of weekly systemic administration of cisplatin with
simultaneous application of local hyperthermia to the pelvic area
induced by electromagnetic radiation. The chemotherapy regimen
was based on our previous experience with weekly administration
of cisplatin (Planting et al, 1993, 1997).
PATIENTS AND METHODS
Patients
Eligibility criteria required histologically proven pelvic recurrence
of cervical cancer in previously irradiated area, not amenable to
surgery. Patients had to have a lesion measurable in one or two
dimensions within the field of combined treatment. For the purpose
of measuring response, computerized tomography (CT) scanning
was mandatory in all patients. Both squamous cell carcinoma and
adenocarcinoma were eligible. Simultaneous metastatic disease
outside the pelvis was not an exclusion criterion. Other eligibility
criteria were performance status (WHO Scale) 0–2, normal bone
marrow functions (white blood cells (WBC) above 3.5 ´ 109 l–1 and
platelets above 100 ´ 109 l–1), serum creatinine below 120 mmol l–1,
or measured creatinine clearance above 50 ml min–1. Patients with
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The Netherlands.prior systemic chemotherapy for recurrent tumour were excluded.
A pacemaker or an artificial hip were absolute contraindications for
hyperthermia treatment. Institutional review board-approved
informed consent was obtained from all patients before study entry.
Cisplatin chemotherapy
Cisplatin was administered once weekly. The administration of the
chemotherapy started with prehydration with 1 litre of normal
saline in 4 h. Cisplatin was then administered in 250 ml saline 3%
over 3 h. An additional 2 litres of normal saline plus 40 mmol
potassium chloride plus 4 g magnesium sulphate was infused over
the next 16 h. As anti-emetic treatment, all patients received
ondansetron 8 mg intravenous (i.v.) bolus plus dexamethasone
10 mg i.v. bolus before the start of cisplatin, followed by
ondansetron 8 mg orally twice daily, and dexamethasone 6 mg
once daily on days 2 and 3. If at scheduled retreatment WBC were
below 2.5 ´ 109 l–1 and/or platelets were below 75 ´ 109 l–1, both
the chemotherapy and hyperthermia treatment were postponed for
1 week. If the treatment had to be postponed for 3 weeks or more
the patient went off study. If renal toxicity or neurotoxicity ³ grade
2 was observed, treatment was stopped. Patients with evidence of
progression at any time during treatment were taken off study and
considered as progressive disease.
Procedure of deep hyperthermia
Immediately after starting with the cisplatin infusion, installation
for deep local hyperthermia of the pelvis commenced; including
placement of thermometry probes, patient positioning, positioning
of the applicator and surface and systemic cooling. For thermom-
etry, probes were placed intraluminally in bladder, vagina and
rectum within closed-tip catheters. Thermal mapping was
performed every 5 min with a stepsize of 1 cm (van der Zee et al,
1998). Temperature measurements were distinguished between
‘tumour contact’, meaning that the site of measurement was in
direct contact with tumour tissue, and ‘tumour indicative’,
meaning that the site of measurements was within the heated
volume around the tumour. Oral temperature was measured every
5 min. For hyperthermia, the BSD-2000 system was available,
including Bowman probes for thermometry (Turner et al, 1989).
Patients were lightly sedated with 1 mg lorazepam. Following
preparations, heating was started with power output at 400 W.
Patients were carefully instructed to mention any unpleasant
sensation which might be the result of a hot spot, such as a burning
sensation, a feeling of pressure, any pain, or bowel or bladder
spasms. The treatment settings for frequency, amplitude distribu-
tion and phase shifting at the start of the first treatment were
chosen on the basis of the two-dimensional pretreatment planning
provided with the BSD-2000 system. Thereafter, treatment
settings were adjusted depending on either information from E-
field measurements or temperature distribution. Information on
temperature distribution came from intraluminally placed ther-
mometry probes, and from the patient. Any pain mentioned by the
patient which disappeared within 1 min following power decrease
was considered to indicate a too high temperature and the treat-
ment settings were adjusted to decrease power input at the specific
location. Adjustments of treatment settings could be either
changes in power output per channel, frequency or phase settings,
or placement of an additional water bolus. Power output was
increased to as high as the patient could tolerate without pain.
Treatment objective was the achievement of a tumour T of ³ 42°C
for a period of 60 min.
The heating-up time was maximum 30 min, therefore effective
heating was to take place during the second hour of the cisplatin
administration. If during heating-up a temperature of 42°C could
not be achieved within 30 min, the 60-min application started at
that time.
Criteria for response and toxicity evaluation and dose-
escalation
The treatment schedule consisted of six weekly combined admin-
istrations of hyperthermia and cisplatin infusions. Response evalu-
ation took place 4 weeks after the last treatment. For response
evaluation and toxicity grading, with the exception of nausea and
vomiting, the WHO criteria were used (WHO, 1979). Toxicity was
reported as the worst grade observed during the whole treatment
period. For grading of nausea and vomiting a modified grading
system was used: grade 0: none; grade 1: mild to moderate nausea
not interfering with adequate fluid and food intake; grade 2:
nausea interfering with adequate fluid and or food intake and/or
vomiting < 5 ´ in 24 h; grade 3: any nausea or vomiting worse than
grade 2 but not requiring i.v. support; grade 4: any nausea and or
vomiting for which hospital admission was necessary.
Patients were evaluable for response if they had completed three
combined treatments, unless there was rapid early progression.
Patients were evaluable for toxicity if they had received at least
one combined treatment.
The starting dose of cisplatin was 60 mg m–2, dose level 1. Dose
level 2 consisted of cisplatin at a dose of 70 mg m–2, dose level 3
of 80 mg m–2. Since we had previously determined cisplatin
85 mg m–2 week–1 to be the maximum tolerable dose without
hyperthermia (Planting et al, 1993), it was decided not to further
escalate above 80 mg m–2 in the present study. At least three
patients were to be entered onto each dose level, until dose-
limiting toxicity was observed. No intra-patient dose escalation
was performed. If one instance of dose-limiting non-haematolog-
ical and/or haematological toxicity were observed among three
patients, an additional three patients were treated at the same dose
level. If dose-limiting toxicity was observed, in only one or two of
six patients, dose escalation was to be continued. If three instances
of dose-limiting toxicity were observed among six patients, an
additional three patients were to be treated at the preceding dose
level. If dose-limiting toxicity was observed at this dose level, in
only one or two patients, this dose level was declared the
maximum tolerated dose (MTD). Dose limiting toxicity was
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Table 1 Patient characteristics
Age median (range) 47 (26–71)
WHO performance
00
11 3
26
Histology
Squamous cell carcinoma 12
Adenocarcinoma 5
Mixed 2
Previous definitive radiotherapy 10
Previous surgery plus radiotherapy 9
Pelvic relapse 17
Pelvic relapse plus distant metastases 2defined as thrombocytopenia grade 4, or neutropenia grade 3 or 4
with fever, renal toxicity ³ grade 2, neurotoxicity ³ grade 2, any
other non-haematological toxicity grade ³ 3.
The dose intensity of cisplatin was calculated as the total
amount of cisplatin administered divided by the total number of
treatment weeks necessary to administer the total dose and is
expressed in milligrams per square meter per week: in patients
completing six treatment cycles in 6 weeks the total dose is divided
by 6: in case of treatment delay the total dose administered is
divided by 6 + the number of weeks delay.
RESULTS
A total of 19 patients were treated. Patient characteristics are
shown in Table 1. Seventeen patients had pelvic recurrence within
previously irradiated area as the sole site of disease. Two patients
simultaneously had distant metastases; one had liver metastases,
the other had pulmonary metastases. One patient had previously
been treated with bleomycin, vindesine, mitomycin-c, cisplatin
(BEMP) induction chemotherapy before definitive radiotherapy.
A total of 89 cycles of local hyperthermia and systemic cisplatin
were administered, the numbers of cycles at each dose-level, the
mean total dose of cisplatin and dose-intensity achieved are shown
in Table 2. Since several patients at dose-level 2 (70 mg m–2)
stopped treatment after three cycles for non-treatment-related
reasons (see below), additional patients were entered onto dose-
level 2 to increase the number of patients that received more than
three cycles. One cycle of cisplatin in one patient was administered
without hyperthermia due to system failure. Leucocytopenia grade
3 (five cases) necessitated postponement of retreatment at cycle 5
or 6 for 1 or 2 weeks, and resulted in 10–15% reduced dose-
intensities in the three dose-levels. The median number of cycles
administered per patient was five (range 3–6). The reasons to stop
treatment before the six scheduled cycles were progressive disease
(five patients with early progression after three cycles), toxicity
(two patients after three, four and five cycles each), and refusal
(one patient after five cycles).
The median tumour volume treated was 150 cm3 (range 21–425)
cm3. Power was applied to a maximum varying from 300 to 900 W
with an average of 607 W (median 600). Maximum tumour
contact temperatures achieved ranged from 39.7–43.6°C with a
mean of 41.6 ± 0.7°C (median 41.6). Maximum tumour indicative
temperatures ranged from 39.3–43.7°C with a mean of 41.8 ±
0.7°C (median 42.1). The oral temperature increased with a mean
of 1.2°C (median 1.1) to a maximum value of 37.2–38.9°C.
Toxicity
The worst toxicity observed in each patient is shown in Table 3.
Even at the highest dose of cisplatin 80 mg m–2 week–1 no dose-
limiting toxicity was observed. As indicated above, grade 3 leuco-
cytopenia at scheduled retreatment resulted in 1 or 2 weeks delay
in five cases. One patient had grade 4 thrombocytopenia after four
cycles and simultaneously refused further treatment, because a
vesicovaginal fistula had developed. This patient had previously
been treated with BEMP induction chemotherapy. Nausea and
vomiting, predominantly occurring during days 2–4 after the
chemotherapy (delayed emesis) developed and worsened during
subsequent courses of chemotherapy and resulted in cessation of
treatment in two patients after five cycles. Neurotoxicity was mild;
grade 1 (five patients) and grade 2 (tinnitus in one patient), and did
not result in withdrawal from protocol treatment. Renal toxicity
grade 1 (four patients) and grade 2 (one patient) was related to
renal function impairment (measured creatinin clearance 50–
60 ml min–1) at the start of treatment and did not necessitate
treatment cessation.
The combined treatment was generally well-tolerated.
Hyperthermia was delivered during 90 min during all cycles in 14
patients; in five patients 11 treatments were stopped after 66–86
min due to intolerable discomfort. In two patients a subcutaneous
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Table 2 Cisplatin dose-intensity achieved
Dose Cisplatin No patients/ Mean total dose of Mean achieved dose intensity Percentage
level dose no administrations cisplatin delivered cisplatin delivereda
(per m2) (per m2) (mg m–2 week–1)
1 60 5/23 276 53 96%
2 70 9/40 311 59 95%
3 80 5/25 400 72 89%
aDenotes mean percentage cisplatin delivered of the planned dose, corrected for reason of withdrawal due to tumour progression.
Table 3 Worst toxicity observed per patient
Toxicity (WHO criteria)
Cisplatin Patients Myelotoxicity Nausea/vomitingb Neurotoxicity Renal toxicity
dose (m2)( n)
01234 01234 01234 01234
6 0 5 2021 a 00 2 3 0 04 1 0 0 03 1 1 0 0
7 0 9 4112 a 1a 15210 81000 7200 0
8 0 5 1112 a 01 1 1 2 01 3 1 0 04 1 0 0 0
a Denotes leucocytopenia (four cases) and thrombocytopenia (one case), causing 1–2 weeks delay in retreatment. bDenotes nausea/vomiting, using modified
criteria, as depicted in Patients and Methods.burn located in the upper leg resulted as a direct hyperthermia
induced toxicity. The clinical symptoms were limited to an indura-
tion in the subcutaneous fat which was tender for 2–3 days and
gradually disappeared.
Responses
All 19 patients were evaluable for response. One patient at dose
level 3 (80 mg m–2) achieved a complete response (CR) that lasted
20 months. Upon relapse of the pelvic tumour this patient was
retreated with six weekly cisplatin cycles plus hyperthermia, and
again achieved a near CR. This second response is now lasting for
9+ months. In addition, nine patients achieved a partial response
(PR); two out of five patients at dose level 1 (60 mg m–2, five out of
nine patients at dose level 2 (70 mg m–2) and two additional
patients (out of five) at dose level 3. The median duration of these
PRs is 6 months (range 4–54+ months). The patient with 54+
months progression-free survival obtained a near CR upon
completion of the protocol treatment, and subsequently underwent
pelvic exenteration salvage surgery. Histological examination
revealed microscopic foci of persistent viable tumour. Therefore,
ten out of 19 patients obtained a response, for an overall response
rate of 53%. Of the remaining patients, one had a NC in the pelvic
tumour after three cycles, but stopped treatment because she had
progressive liver metastases. One patient had NC after six cycles
that lasted five months, and seven patients had progression (PD) at
the time of evaluation. There were no differences between respon-
ders and non-responders for tumour contact temperatures, tumour
indicative temperatures, tumour volume, oral temperature increase
or total power applied (data not shown).
DISCUSSION
Surgery or radiotherapy, or a combination of these two modalities,
continue to be the primary treatment options for invasive cervical
cancer. However, following surgery plus post-operative radio-
therapy, or primary definitive radiation therapy, or radiotherapy for
recurrent pelvic disease up to 40% of patients will develop pelvic
recurrent disease. With the exception of salvage surgery as a treat-
ment option in some of these patients, the use of systemic
chemotherapy is the only remaining treatment modality. Cisplatin
has emerged as the most active single agent for treating patients
with metastatic disease; no other standard cytotoxic drug has been
associated consistently with objective response rates of 25% or
higher. However, in patients who experience relapses following
definitive radiation therapy cisplatin has only a minor effect, if
any, on the natural history of the disease (Brader et al, 1998). The
effectiveness of chemotherapy for patients with recurrent cervical
cancer is compromised by the problems of drug distribution
resulting from prior pelvic irradiation (Hopewell, 1983). In addi-
tion, it is likely that recurrent or persistent foci of cancer after
radiotherapy represent more resistant disease (Osmak et al, 1989).
In a study by Potter et al (1989) the complete response rate to
cisplatin in patients with distant metastases was 53%, with an
overall response rate of 73%, whereas no complete responses and
no more than seven partial responses (21%) were obtained in 33
patients with localized pelvic recurrence or persistent disease
(Potter et al, 1989). In a report by Lele et al (1989) on 67 patients
with cervical cancer who were treated with weekly cisplatin
chemotherapy, the response rates by site were: liver 33%, lymph
nodes 40%, lung 48%, whereas only one out of 24 patients with a
pelvic recurrence (4%) obtained a response. Therefore, new
approaches to the management of pelvic recurrent disease are
clearly warranted.
Research in animal and human cell cultures has provided
evidence that a number of chemotherapeutic agents, cisplatin in
particular, have cytotoxicity that is significantly enhanced at
elevated temperatures. Cytotoxicity of cisplatin increases almost
linear with increasing temperature and maximal potentiation
occurs when hyperthermia and cisplatin are administered simulta-
neously. The exact mechanism of potentation remains to be eluci-
dated, but increased intracellular uptake, as well as increased DNA
damage in the interactive effect, and impairment of DNA strand-
break repair have been shown (Dahl, 1995).
The application of deep local hyperthermia with the systemic
administration of cisplatin in patients with pelvic recurrent
cervical cancer thus appears an attractive notion. Following initial
feasibility data on the clinical use of combined cisplatin and local
hyperthermia treatment (Green et al, 1989), Rietbroek et al
recently reported on a phase II study of combined weekly loco-
regional hyperthermia and systemic administration of cisplatin in
patients with previously irridiated recurrent cervical carcinoma
(Rietbroek et al, 1996, 1997). By using a regimen of cisplatin of
50 mg m–2 week-1 with 1 week interruption after every four cycles
for a total of 12 cycles, projected dose-intensity 40 mg m–2 week–1,
these authors observed an overall response in 12 of 23 patients,
52% (95% confidence interval (CI) 31–73%). Additional salvage
surgery became possible in three responding patients, whose
tumours were previously considered unresectable.
We conducted a phase I/II study based on our previous experi-
ence with weekly cisplatin at a considerably higher dose-intensity
(Planting et al, 1993, 1997); weekly local hyperthermia was
combined with cisplatin for a total of six cycles at cisplatin dose
levels (and projected dose-intensity of six cycles in 6 weeks) 60,
70 and 80 mg m–2 week–1. We found that this combined hyper-
thermia-dose-intensive cisplatin regimen was well-tolerated, with
no dose-limiting toxicity observed at the highest dose level of
80 mg m–2 week–1 tested. Cisplatin was not escalated above
80 mg m–2, since we had previously demonstrated in patients
treated with cisplatin without concurrent hyperthermia that
cisplatin 80 mg m–2 weekly is the maximum tolerated dose. We
have thus demonstrated that local hyperthermia and cisplatin can
be safely combined and that hyperthermia does not adversely
impact the tolerability of cisplatin given at maximum tolerated
single modality dose.
With the use of this weekly times 6 hyperthermia plus dose-
intensive cisplatin regimen we obtained one complete response
and nine partial responses in a total of 19 patients, for an overall
response rate of 53%. The median duration of response was 6
months (range 4–54+ months).
One patient with a near complete response subsequently under-
went salvage surgery and currently remains free of disease at 4
years.
The true impact of the use of the combination of cisplatin and
locoregional hyperthermia can only be answered in a randomized
study of chemotherapy alone versus the combined treatment.
Nonetheless, based on the existing data of the poor efficacy of
cisplatin when used as single treatment modality, and the
favourable reports on the combined treatment now available which
resulted in over 50% response rates in previously irradiated pelvic
recurrent cervical carcinoma (Rietbroek et al, 1997 and present
study), we believe that the combined modality approach of weekly
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tion regimen, particularly in patients for whom the option of subse-
quent salvage surgery is available.
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